Who We Are

We have been the industry leader for more than a decade.

With over 15 years of experience, we’ve amassed over 500 therapeutic antibody campaigns with over 115 partners, ranging from top-20 pharma companies to biotech companies to leading academic institutions. 

With more than 70 clinical programs originating from our platform, Adimab is the industry leader in translating your target hypotheses into therapeutically relevant antibody drugs.

Leadership

Philip Chase

Chief Executive Officer

Eric Krauland, PhD

President and Chief Scientific Officer

Ryan McGovern

Chief Financial Officer

Guy Van Meter

Chief Business Officer

Max Vásquez, PhD

Chief Computing Officer

Robert Pejchal, PhD

Vice President, Antibody Engineering

Kristin Rookey

Vice President, Strategic Alliances

Marianne Thomson

Vice President, Human Resources

Amy Bray, PhD

Senior Director, Legal

Kirt Johnson

Senior Director, Product Engineering & Operations

Juergen Nett, PhD

Senior Director, High-throughput Expression

Katy Seneca

Senior Director, Finance & Accounting

Paul Widboom, PhD

Senior Director, Antibody Engineering

Leadership

Philip Chase

Chief Executive Officer

Eric Krauland, PhD

President and Chief Scientific Officer

Ryan McGovern

Chief Financial Officer

Guy Van Meter

Chief Business Officer

Max Vásquez, PhD

Chief Computing Officer

Robert Pejchal, PhD

Vice President, Antibody Engineering

Kristin Rookey

Vice President, Strategic Alliances

Marianne Thomson

Vice President, Human Resources

Amy Bray, PhD

Senior Director, Legal

Kirt Johnson

Senior Director, Product Engineering & Operations

Juergen Nett, PhD

Senior Director, High-throughput Expression

Katy Seneca

Senior Director, Finance & Accounting

Paul Widboom, PhD

Senior Director, Antibody Engineering

Board of Directors

ARCLogo
Arc
Adimab Royalty Company
("ARC") controls the royalty rights to Adimab's most advanced therapeutic programs.

Board of Directors

ARCLogo
Arc
Adimab Royalty Company
("ARC") controls the royalty rights to Adimab's most advanced therapeutic programs.

Our Culture

At Adimab, we value the whole individual and foster a collaborative work environment where we all feel welcomed, appreciated, and connected – to one another and our mission of making a meaningful impact on human health.

We are committed to providing an engaging and supportive work environment that encourages employees to pursue their passions and develop professionally.

Transparency and open communication are integral to our culture. We empower our employees by providing regular opportunities to share their feedback and ideas openly.

Scroll to Top

Leadership

Leadership

Philip Chase

Chief Executive Officer

Philip T. Chase has served as the Chief Executive Officer of Adimab since 2022. Prior to his appointment as CEO, he served as Adimab’s General Counsel for more than 10 years. Before joining Adimab, Mr. Chase provided legal and business counsel for numerous biotechnology companies, including Alnylam Pharmaceuticals, RenaMed, EPIX Pharmaceuticals and Transkaryotic Therapies. Prior to joining the biotechnology industry, Mr. Chase worked at the law firms of Skadden, Arps, Slate, Meagher & Flom LLP and Shearman & Sterling LLP. He received his JD from Columbia University School of Law and his BA from Colby College.

Leadership

Leadership

Eric Krauland, PhD
President and Chief Scientific Officer

Dr. Eric Krauland is the Chief Scientific Officer and President of Adimab and has been with the company for 16 years. Dr. Krauland has worked in numerous roles at Adimab since 2007 and was a key contributor in the development of Adimab’s platform. He received his PhD in Biological Engineering from the Massachusetts Institute of Technology in 2007 and his BS/MSE in Biomedical Engineering from Johns Hopkins University.

Leadership

Leadership

Ryan McGovern
Chief Financial Officer

Ryan McGovern is the Chief Financial Officer of Adimab and has been with the company since 2009. Before joining Adimab, Mr. McGovern was a management consultant at OC&C Strategy Consultants and held various accounting and audit roles at Deloitte. He earned his MBA from the Tuck School of Business at Dartmouth, his MS from Boston College, and his BS from Northeastern University.

Leadership

Leadership

Guy Van Meter
Chief Business Officer

Guy Van Meter is the Chief Business Officer of Adimab and has been with the company for 15 years. Before joining Adimab, Mr. Van Meter was part of Pfizer’s Business Development team for their RNAi and Regenerative Medicine divisions. Prior to Pfizer, he managed the antibody technology business for Dyax Corp for six years, generating more than 50 partnerships. He also worked in product development at Alkermes, worked as a Research Associate at both Harvard and Yale, and earned his MBA from Babson’s FW Olin Graduate School of Business.

Leadership

Leadership

Max Vásquez, PhD
Chief Computing Officer

Dr. Max Vásquez is the Chief Computing Officer, having joined Adimab in 2007. Before joining Adimab, Dr. Vásquez was a Principal at Bocaracá Consulting in Palo Alto, CA, a healthcare consulting practice focused on antibody discovery and engineering. Prior to Bocaracá Consulting, Dr. Vásquez served in the position of Senior Director, Research, at PDL Pharma in Freemont, CA, where he was involved in all efforts of antibody discovery, including antibody humanization, antibody engineering, bioinformatics, target validation, and preclinical development. Dr Vásquez earned his PhD in Chemistry from Cornell University.

Leadership

Leadership

Robert Pejchal, PhD
Vice President, Antibody Engineering

Robert Pejchal is Vice President of Antibody Engineering at Adimab, and has been at Adimab for 11 years. Before joining Adimab, Dr. Pejchal was a Postdoctoral Fellow at The Scripps Research Institute. He earned his PhD in Biological Chemistry from the University of Michigan and his BS from Brandeis University.

Leadership

Leadership

Kristin Rookey
Vice President, Strategic Alliances

Kristin Rookey is Vice President of Strategic Alliances, having joined Adimab in 2012 to create and run the company’s Alliance Management group. Before Adimab, she spent 11 years as a Principal Scientist at Dyax Corp, as a researcher, including part of the team that built their core antibody phage display platform. Prior to Dyax Corp, Kristin Rookey worked as a Researcher at Anadys Pharmaceuticals, a company sold to Roche Pharmaceuticals in 2011. 

Leadership

Leadership

Marianne Thomson
Vice President, Human Resources

Marianne Thomson is Vice President, Human Resources. Before joining Adimab, she was Associate Dean of Student Affairs at Dartmouth College, and Associate Vice President of Student Experience and Dean of Students at Syracuse University. Previously, Dr. Thomson spent more than eight years at American University and taught at George Washington University. She received her EdD and MA in Higher Education Administration from George Washington University and her BA from Georgetown University.

Leadership

Leadership

Amy Bray, PhD
Senior Director, Legal

Amy Bray is Senior Director of Legal and has been with Adimab for 6 years. Before joining Adimab, Dr. Bray was an Associate at the law firms Sterne, Kessler, Goldstein & Fox and LeClairRyan, as well as a Law Clerk at Hunton & Williams LLP. She earned her JD at the American University Washington College of Law and her PhD in Biochemistry from the University of Texas Southwestern Medical Center.

Leadership

Leadership

Kirt Johnson
Senior Director, Product Engineering & Operations

Kirt Johnson is Senior Director, Product Engineering & Operations, having joined Adimab in 2012. Before joining Adimab, Mr. Johnson spent nearly five and a half years as Director of Product Development at NextMark. He has also worked at King Arthur Flour Company, Obsidian Healthcare Disclosure Services, and Affinity Internet. Mr. Johnson spent nearly four years at Bigstep.com, where he was Director of Engineering. He began his career with engineering roles at vivid Studios, Nvolve, IDG, and WIRED Magazine, and earned his BA from Wesleyan University.

Leadership

Leadership

Juergen Nett, PhD
Senior Director, High-throughput Expression

Juergen Nett is Senior Director, High-throughput Expression, and has spent more than nine and a half years working in high-throughput expression at Adimab. Before joining Adimab, Dr. Nett spent nearly eight years at Merck, working in high-throughput screening and strain selection. He also worked as a Senior Scientist at GlycoFi and completed his postdoctoral research at Dartmouth Medical School. Dr. Nett earned his PhD in Biochemistry from the Technical University of Kaiserslautern.

Leadership

Leadership

Katy Seneca

Senior Director, Finance & Accounting

Katy Seneca is Senior Director, Finance & Accounting, and has spent over 11 years working in finance and accounting at Adimab. Prior to joining Adimab, she worked as a Senior Audit Associate at AKT LLP, CPAs and Business Consultants. Before AKT, she was a Senior Accountant at Gallagher, Flynn & Company, LLP. Mrs. Seneca is a certified public accountant and received her BS from Saint Michael’s College.

Leadership

Leadership

Paul Widboom, PhD
Senior Director, Antibody Engineering

Paul Widboom is Senior Director, Antibody Engineering, and has spent 13 years working in antibody engineering at Adimab. Before joining Adimab, Dr. Widboom completed postdoctoral work at Massachusetts Institute of Technology. He received his PhD in Chemistry from Boston College and his BS from Wheaton College.

Board of Directors

Board of Directors

Philip Chase

Chief Executive Officer

Philip Chase is the Chief Executive Officer of Adimab, after he served more than 10 years as General Counsel for the company. Before joining Adimab, Mr. Chase provided legal counsel for numerous biotechnology companies, including Alnylam Pharmaceuticals, RenaMed, EPIX Pharmaceuticals and Transkaryotic Therapies. Prior to joining the biotechnology industry, Mr. Chase worked at the law firms of Skadden, Arps, Slate, Meagher & Flom LLP and Shearman & Sterling LLP. He received his JD from Columbia University School of Law and his BA from Colby College.

Board of Directors

Board of Directors

Eric Krauland, PhD
President and Chief Scientific Officer
Dr. Eric Krauland is the Chief Scientific Officer and President of Adimab and has been with the company for 16 years. Dr. Krauland has worked in numerous roles at Adimab since 2007 and was a key contributor in the development of Adimab’s platform. He received his PhD in Biological Engineering from the Massachusetts Institute of Technology in 2007 and his BS/MSE in Biomedical Engineering from Johns Hopkins University.

Board of Directors

Board of Directors

Nancy Thornberry
Founding CEO and Chair, R&D, Kallyope

Nancy Thornberry has decades of experience in the pharmaceutical and biotech industries, with responsibilities spanning research and development, business development, customer engagement, and strategy. From 2015-2021 she was CEO of Kallyope, a NYC-based biotechnology company focused on the discovery and development of novel therapeutic agents targeting the gut and gut-brain axis. She remains on the Board of Directors and is Chair of R&D. Prior to joining Kallyope, she was Senior Vice President and Franchise Head, Diabetes and Endocrinology, for Merck & Co. Inc. In this role, she led discovery and clinical research in diabetes, obesity, osteoporosis, fertility, and contraception. Before becoming Franchise Head, Nancy initiated and led Merck’s dipeptidyl peptidase 4 (DPP-4) project, which resulted in the discovery of JANUVIA® for the treatment of Type 2 diabetes.

Board of Directors

Board of Directors

Tillman U. Gerngross, PhD
Co-Founder and Executive Chairman of the Board

Professor Tillman Gerngross is a Co-Founder of Adimab and the Chairman of the Board. He served as the Chief Executive Officer from the creation of the company until 2022. He is a Professor of Bioengineering at the Thayer School of Engineering at Dartmouth College, and an Adjunct Professor in the Departments of Biology and Chemistry at Dartmouth. Prof. Gerngross is a founder in numerous companies, including GlycoFi, Arsanis, Alector, Avitide, Amagma, Ankyra, and Invivyd. He received an MS in Chemical Engineering and his PhD in Molecular Biology from the Technical University of Engineering of Vienna.

Board of Directors

Board of Directors

Mike Ross, PhD
Managing Partner, SV Health Investors

Mike’s career spans more than two decades in venture capital, following 21 years in senior operating executive roles for leading biotechnology companies. He joined SV Health Investors as a Venture Partner in 2001 and became a Managing Partner in 2002. Mike was the tenth employee at Genentech, where he worked for 13 years. He served as Genentech team leader for the Humulin®, Roferon®, and Protropin® programs and was Vice President of Development during the development of Activase®, Nutropin®, and Pulmozyme®. He then started Genentech’s antibody engineering, protein engineering, and small-molecule discovery effort as Vice President of Medicinal and Biomolecular Chemistry. Mike was the Founding Chief Executive Officer (CEO) of Arris Pharmaceutical, MetaXen, ExSAR, and CyThera (now Viacyte). Mike received his PhD in Chemistry from the California Institute of Technology (Caltech) and went on to do his post-doctoral work at Harvard. He serves on the Board of the Thayer School of Engineering at Dartmouth College. Mike has served on numerous venture and public biotech boards.

Board of Directors

Board of Directors

Terry McGuire
Managing Partner, Polaris Partners

As a Founding Partner of Polaris Partners, Terry McGuire brings more than 30 years of successful early stage investing experience in medical and information technology companies. Terry has invested in more than 50 companies. Terry is chairman of the Thayer School of Engineering, Dartmouth College. He also sits on the boards of MIT’s The David H. Koch Institute for Integrative Cancer Research, The Arthur Rock Center for Entrepreneurship at Harvard Business School, and The Healthcare Initiative Advisory Board (HBS). Terry holds an MBA from Harvard Business School, an MS in engineering from The Thayer School at Dartmouth College, and a BS in physics and economics from Hobart College.

Board of Directors

Board of Directors

Ajay Royan
Founder and Managing General Partner, Mithril Capital Management

Ajay Royan cofounded Mithril and heads the firm as its managing general partner. At Mithril, Ajay has led investments in innovative companies located both within Silicon Valley and around the world. He serves on many of these companies’ boards, including C2FO, AppDirect, Adimab, and Auris, helping them successfully navigate high-growth periods by working with founders on competitive and organizational strategy, as well as macro trends. Before forming Mithril, Ajay was a managing director and senior investor at Clarium Capital Management, where he led unlevered growth investments and was a member of the core team that grew the firm into a multi-billion dollar fund. Ajay began his career at Braxton Associates, a unit of Deloitte, where he specialized in corporate strategy. Ajay serves on the Science Advisory Board of the Oak Ridge National Laboratory and was elected to the Presidents’ Circle of the National Academies of Science, Engineering, and Medicine. He was educated at Yale University.

Board of Directors

Board of Directors

Guy Van Meter
Chief Business Officer

Guy Van Meter is the Chief Business Officer and has been with the company for 15 years. Before joining Adimab, Mr. Van Meter was part of Pfizer’s Business Development team for their RNAi and Regenerative Medicine divisions. Prior to Pfizer, he managed the antibody technology business for Dyax Corp for six years, generating more than 50 partnerships. He also worked in product development at Alkermes, worked as a Research Associate at both Harvard and Yale, and earned his MBA from Babson’s FW Olin Graduate School of Business.

Board of Directors

Board of Directors

Greg Brown
Chief Executive Officer at Memgen

Gregory B. Brown, MD was appointed to Memgen’s Board in October 2016 and was elected Chairman on February 16, 2017. Dr. Brown is currently Chief Executive Officer of Memgen, Inc., a development-stage biotechnology company. In 2007, Dr. Brown co-founded and remains Vice Chairman of HealthCare Royalty Partners (“HCR Partners”). He has been involved in sourcing, performing due diligence on and closing more than $1 billion of royalty financings. Before co-founding HCR Partners, Dr. Brown was a partner at Paul Capital Partners where he co-managed that firm’s royalty investments as a member of the royalty management committee. Prior to beginning his principal investment career in 2003, Dr. Brown was co-head of investment banking and head of healthcare at Adams, Harkness & Hill (now Canaccord Genuity) and a ranked biotechnology research analyst at Vector Securities International. Dr. Brown holds a BA from Yale, an MD from SUNY Upstate Medical Center and an MBA from Harvard Business School.

Board of Directors

Board of Directors

Ryan McGovern

Chief Financial Officer

Ryan McGovern is the Chief Financial Officer of Adimab and has been with the company since 2010. Before joining Adimab, Mr. McGovern served as Advisory Council for Live Free and Start, an initiative of the New Hampshire High Tech Council aimed at creating jobs and fostering innovative businesses. Previously, he worked in consulting roles at OC&C Strategy Consultants and Deloitte. He earned his MBA from the Tuck School of Business at Dartmouth, his MS from Boston College and his BS from Northeastern University.